Unadjusted changes in disease activity and HAQ at 6 and 12 months* after initiation of TCZ in patients with low vs high comorbidity burden.
| Outcome | Low Burden* (mCCI < 2), n = 575 | High Burden* (mCCI ≥ 2), n = 195 | Unadjusted Difference or OR† | p |
|---|---|---|---|---|
| 6 months | ||||
| Continuous outcome | ||||
| Change in CDAI | −7.57 (13.65) | −7.72 (13.62) | −0.15 (−2.37–2.07) | 0.897 |
| Change in HAQ | −0.05 (0.41) | −0.09 (0.43) | −0.04 (−0.11–0.30) | 0.263 |
| Binary outcome | ||||
| Achievement of MCID, CDAI | 50.87% | 44.62% | 0.78 (0.45–1.41) | 0.132 |
| Achievement of MCID, HAQ | 29.96% | 31.79% | 1.09 (0.76–1.55) | 0.638 |
| Achievement of LDA | 24.70% | 21.54% | 0.84 (0.57–1.24) | 0.372 |
| 12 months | ||||
| Continuous outcome | ||||
| Change in CDAI | −8.42 (14.24) | −7.82 (14.52) | 0.59 (−1.74–2.92) | 0.617 |
| Change in HAQ | −0.05 (0.40) | −0.11 (0.42) | −0.06 (−0.13–0.01) | 0.080 |
| Binary outcome | ||||
| Achievement of MCID, CDAI | 52.28% | 49.74% | 0.90 (0.65–1.25) | 0.541 |
| Achievement of MCID, HAQ | 27.09% | 30.05% | 1.16 (0.81–1.66) | 0.429 |
| Achievement of LDA | 30.43% | 31.28% | 1.04 (0.73–1.48) | 0.825 |
↵* Continuous outcomes expressed as mean (SD); binary outcomes expressed as percent response rate.
↵† Continuous outcomes expressed as β (95% CI); binary outcomes expressed as OR (95% CI). CDAI: Clinical Disease Activity Index; HAQ: Health Assessment Questionnaire; LDA: low disease activity; mCCI: modified Charlson Comorbidity Index; MCID: minimum clinically important difference; TCZ: tocilizumab.